TRG
Tissue Regenix Group

7 January 2026

Tissue Regenix Group Ltd

Admission Statement

The Board of Tissue Regenix Group, a leading medical device company in regenerative medicine today announce the admission of its Ordinary Shares to trading on Asset Match ahead of its first auction.

It is intended that the first auction in the Company's shares will be held in February 2026. Thereafter, auctions are expected to be held every month. More information, including exact auction dates and details on how to buy and sell, are available on the company profile page.

The Directors of the Company are:
Jay LeCoque *(Executive Chairman)*
Kirsten Lund *(CFO and Company Secretary)*
Judy Madden *(Chief Operating Officer)*

Registered office:
Unit 3, Phoenix Court, Lotherton Way, Garforth, LS25 2GY

1. Company Description
Tissue Regenix is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold that is not rejected by the patient's body and can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle injuries, and wound care.

In August 2017, Tissue Regenix acquired CellRight Technologies®. This biotech company specialises in regenerative medicine and is dedicated to developing high-quality, innovative tissue scaffolds to enhance healing opportunities in defects created by trauma and disease. CellRight's human tissue products may be used in spine, trauma, general orthopaedic, dental and ophthalmological surgical procedures.

2. Strategy and Prospects
Our focus on the 4S strategic elements of Supply, Sales Revenue, Sustainability and Scale continues to provide the foundation of how we operate, execute and drive growth.

The continued investment that we are making and the focus we are placing on tissue Supply has enabled us to sustain and grow in line with our business needs as well as manage the inventories more efficiently and provide tissue to other tissue processors. Processing capacity, another key element in Supply, has kept pace with the Group's growth despite resource-related headwinds, as experienced more broadly across numerous industries.

Our focus on Sales Revenue and Sustainability has been realised in revenue growth and a positive adjusted EBITDA for the year. Our ability to increase our cash balance in the second half of 2023 was a milestone for the organisation and a further demonstration of Sustainability. Obtaining the regulatory approvals for our third-party logistics partner provides us the opportunity and flexibility to

Scale our allograft business in markets outside the U.S. ('OUS'). The Group's solid 4S foundation enables us to continue growth plans for Tissue Regenix and deliver shareholder value.

3. Board of Directors
Brief biographies of the Directors of the Company are set out below.

Jay LeCoque - Executive Chairman
Jay has over 30 years of senior management experience focused on global healthcare diagnostics and clinical life sciences. Jay is the current CEO and Executive Chairman of Source BioScience since being appointed in 2017. He was an Executive Director of Bioquell plc from 2016 until its acquisition by ECOLAB in 2019. Prior to that, he was CEO of Celsis International plc from 2000 to 2009, and remained CEO following a public to private transaction in 2009 to form Celsis International Ltd until its acquisition in 2015. Jay earned a BS in Business Administration and Marketing from Miami of Ohio University and his MBA from Northwestern University Kellogg School of Management.

Kirsten Lund - CFO and Company Secretary
Kirsten Lund oversees all financial strategy, planning, and operations for Tissue Regenix. With more than 15 years of finance experience, she brings deep expertise in financial leadership and strategic business growth. Kirsten joined Tissue Regenix in 2010 and has progressed through several senior roles within the company. She served as Group Financial Controller for three years before being appointed Group Finance Director in November 2019, a position she held until January 2022. She then transitioned to EMEA Director, working closely with the management team to help drive the company's strategic expansion into new markets. Drawing on her extensive experience in the healthcare sector, Kirsten provides invaluable insight into company structure and routes to market. Kirsten holds a Bachelor of Science degree from the University of Derby and achieved her ACCA qualification in 2015.

Judy Madden - COO
Judy has over 25 years of senior management experience in commercial and operations management in global life science companies. She held senior management roles at Charles River Laboratories from 2015 though 2024 including Executive Director of Celsis, and General Manager of Accugenix. Judy was Vice President, Corporate Development for Celsis international prior to its acquisition by Charles River in 2015. Prior to that she served in senior marketing and product development roles at medical device maker, Advanced Bionics.

Judy holds a HBA degree in Marketing and Business Administration from Ivey Business School at Western University in London, Canada.

4. Share capital and significant shareholders
On 7 January 2026 the Company's issued share capital consisted of 871,395,635 Ordinary Shares with 0.1 pence par value, each share having equal voting rights.

The Ordinary Shares are not admitted to trading on any exchange or trading platform other than Asset Match, having exited the Alternative Investment Market ("AIM") effective 7 January 2026.

The Company has been notified that the following shareholder(s) are interested in 3% or more of the issued share capital of the company:

Name of shareholder	*Number of Ordinary Shares*	*Percentage holding*
Harwood Capital (London)	815,730,000	93.61%

5. Financial statements
The Company's latest results for 12-month period ended 31 December 2024 can be accessed on the company profile page.

6. Legal and Arbitration Proceedings
During the 12 months preceding the date of this document, neither the Company nor any of its subsidiaries has been engaged in or is currently engaged in any litigation or arbitration proceedings which have or may have had in the recent past a significant effect on the financial position of the Company and so far as the directors are aware, there are no such proceedings pending or threatened by or against the Company or any of its subsidiaries.

7. Responsibility Statement
The Directors of Tissue Regenix Group Ltd, as set out above, accept responsibility for the information contained within this document. To the best of the knowledge and belief of the directors (who have taken reasonable care to ensure that such is the case) the information contained in this document is in accordance with the facts and does not omit anything likely to affect the import of such information.

REMINDER: It is intended that the first auction in the Company's shares will be held in **February 2026**. Thereafter, auctions will be held at regular intervals. More information, including exact auction dates and details on how to buy and sell, will be provided via the Company's auction page.

-- ENDS --